San Francisco Bay Area biotech stories.
Friday, August 24, 2012
Theravance, GSK to start approval process for COPD drug by end of year
Theravance CEO Rick Winningham.
and partner GlaxoSmithKline wrapped up clinical trials around a drug that the companies could start submitting for regulatory approval later this year for chronic obstructive pulmonary disease
. The once-a-day drug — called UMEC/VI for the molecules umeclidinium bromide and vilanterol — is one in a series of treatments that GlaxoSmithKline (NYSE: GSK) and South San Francisco-based Theravance (NASDAQ: THRX) hope to eventually sell to asthma or COPD patients.
GSK and Theravance said Friday
that they would start to submit UMEC/VI for regulatory approval "from the end of 2012."
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)